抗体相关的联盟和授权合约 (2019～2024年)

本报告提供抗体相关的近来 (2019～2024年) 的联盟授权合约趋势相关分析，彙整整体交易数量的转变，及财务方面 (付款条件) 的倾向，由于主要企业 (全25公司) 的交易形成的动向，契约条件的倾向，各技术详细内容趋势等调查，近几年主要的联盟交易内容等详细资讯，为您概述为以下内容。

目录

摘要整理

第1章 简介

第2章 抗体相关的交易形成的倾向

• 简介
• 抗体相关交易的长期趋势
• 抗体相关最活跃的交易业者
• 抗体相关的交易:各交易类型
• 抗体相关的交易:各治疗领域
• 抗体相关的交易:各业界
• 抗体相关的交易:交易条件
  • 抗体相关的交易:交易总额
  • 抗体相关的交易:预付款金
  • 抗体相关的交易:阶段性付款
  • 抗体相关的交易:使用费率

第3章 抗体相关的主要交易

• 简介
• 抗体相关的主要的交易:以契约金额为准

第4章 抗体相关最活跃的交易企业

• 简介
• 抗体相关交易上最活跃的企业
• 抗体相关交易上最活跃的企业:简介

第5章 抗体相关的契约缔结一览

• 简介
• 抗体相关的契约缔结一览

第6章 抗体相关的交易:各技术种类

• 交易一览
• 交易一览:抗体相关，各企业 (ABC顺序)
• 交易一览:抗体相关，各交易类型
• 交易一览:抗体相关，各治疗领域
• 交易的种类定义
• 关于Biopharma Research Ltd
• 目前联盟
• 目前契约
• Current Partnering出版的最近报告标题

Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the antibody deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of antibody deals from 2019 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 1328 antibody deals announced since 2019 including financial terms where available including links to online deal records of actual antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of antibody dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in antibody dealmaking since 2019.

Chapter 3 provides an overview of the leading antibody deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibody dealmaking with a brief summary followed by a comprehensive listing of antibody deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of antibody deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of antibody partnering deals signed and announced since Jan 2019. The chapter is organized by specific antibody technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in antibody deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse antibody collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of antibody trends and structure of deals entered into by leading biopharma companies worldwide.

Antibody Collaboration and Licensing Deals includes:

• Trends in antibody dealmaking in the biopharma industry
• Directory of antibody deal records covering pharmaceutical and biotechnology
• The leading antibody deals by value
• Most active antibody licensing dealmakers
• Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking

• 2.1. Introduction
• 2.2. Antibody deals over the years
• 2.3. Most active antibody dealmakers
• 2.4. Antibody deals by deal type
• 2.5. Antibody deals by therapy area
• 2.6. Antibody deals by industry sector
• 2.7. Deal terms for antibody deals
  • 2.7.1 Antibody deals headline values
  • 2.7.2 Antibody deal upfront payments
  • 2.7.3 Antibody deal milestone payments
  • 2.7.4 Antibody royalty rates

Chapter 3 - Leading antibody deals

• 3.1. Introduction
• 3.2. Top antibody deals by value

Chapter 4 - Most active antibody dealmakers

• 4.1. Introduction
• 4.2. Most active antibody dealmakers
• 4.3. Most active antibody deals company profiles

Chapter 5 - Antibody contracts dealmaking directory

• 5.1. Introduction
• 5.2. Antibody contracts dealmaking directory

Chapter 6 - Antibody dealmaking by technology type

• Deal directory
• Deal directory - Antibody deals by company A-Z
• Deal directory - Antibody deals by deal type
• Deal directory - Antibody deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Antibody deals since 2019
• Figure 2: Active antibody dealmaking activity - 2019 - 2024
• Figure 3: Antibody deals by deal type since 2019
• Figure 4: Antibody deals by therapy area since 2019
• Figure 5: Antibody deals by industry sector since 2019
• Figure 6: Antibody deals with a headline value
• Figure 7: Antibody deals with an upfront value
• Figure 8: Antibody deals with a milestone value
• Figure 9: Antibody deals with a royalty rate value
• Figure 10: Top antibody deals by value since 2019
• Figure 11: Most active antibody dealmakers 2019 - 2024
• Figure 12: Antibody deals by technology type since 2019